✦ LIBER ✦

68. Randomized trial between the selective aromatase inhibitor formestane (Lentaron) or tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer: confirmation of bioequivalence in survival

✍ Scribed by C.M. Royce; L. Mauriac; R. Pérez Carrion; V. Alberola; F. Calabresi; R.Th. Michel; R. Santos; E. Wehrle

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

365 Randomized trial between selective a

✍ L. Mauriac; R. Pérez Carrion; V. Alberola; F. Calabresi; R.Th. Michel; R. Santos 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Randomized trial or the selective aromat

✍ R. Peréz-Carrion; V. Alberola; F. Calabresi; R-Th. Michel; R. Santos; M. Fehling 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 298 KB

Anastrozole (‘Arimidex’) versus tamoxife

✍ Beat Thürlimann; Dagmar Hess; Dieter Köberle; Isabella Senn; Pierluigi Ballabeni 📂 Article 📅 2004 🏛 Springer US 🌐 English ⚖ 348 KB

NSABP B-42: A Clinical Trial to Determin

✍ Eleftherios P. Mamounas; Barry Lembersky; Jong-Hyeon Jeong; Walter Cronin; Barba 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 117 KB